Adhera Therapeutics (ATRX)

Overall impact
B (73)

Commentary

Adhera Therapeutics is a strong overall performer. With a 'B' rating of 73.2 for overall impact (87th percentile compared to all companies), Adhera Therapeutics ranks 194th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 190 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 388 others. On top material causes for Adhera Therapeutics's industry (Pharmaceuticals & Biotech), Adhera Therapeutics performs well in Humane Treatment of Animals (95.6 score), Child and Maternal Health (93.0), Reduced Use of tobacco (95.5) and 5 other causes where it received an 'A' score and performs poorly in Technology Innovation (12.5 score), Reduced Green House Gas Emissions (36.3) and Disaster Readiness and Effective Aid (33.3).
Impact
Cause ATRX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
La, United States
Share classes
ATRX
Description
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease and MLR-1023 to treat Type 1 diabetes. Adhera Therapeutics, Inc. was formerly known as Marina Biotech, Inc. and changed its name in October 2018. The company is based in Baton Rouge, Louisiana.
Material causes
Ethos considers the following causes material for Adhera Therapeutics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.